Cargando…
Desmoglein-2 as a prognostic and biomarker in ovarian cancer
Greater than 80% of all cancer cases are carcinomas, formed by the malignant transformation of epithelial cells. One of the key features of epithelial tumors is the presence of intercellular junctions, which link cells to one another and act as barriers to the penetration of molecules. This study as...
Autores principales: | Kim, Jiho, Beidler, Peter, Wang, Hongjie, Li, Chang, Quassab, Abdullah, Coles, Cari, Drescher, Charles, Carter, Darrick, Lieber, André |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722792/ https://www.ncbi.nlm.nih.gov/pubmed/33218274 http://dx.doi.org/10.1080/15384047.2020.1843323 |
Ejemplares similares
-
In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4
por: Wang, Hongjie, et al.
Publicado: (2022) -
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14
por: Wang, Hongjie, et al.
Publicado: (2010) -
Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015) -
Translational development of a tumor junction opening technology
por: Kim, Jiho, et al.
Publicado: (2022) -
Autoantibodies against desmoglein 2 are not pathogenic in pemphigus()
por: Miguel, Marcela Calixto Brandão, et al.
Publicado: (2022)